This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, A. Articles by Pardee, A. B. Search for Related Content PubMed PubMed Citation Articles by Wang, A. Articles by Pardee, A. B.

Cancer Chemotherapy by Deoxynucleotide Depletion and E2F-1 Elevation

¹ ArQule Biomedical Institute, ArQule Inc., Woburn, Massachusetts; ² Vattikuti Urology Institute, Henry Ford Health System, Detroit, Michigan; and ³ Dana-Farber Cancer Institute, Boston, Massachusetts

Requests for reprints: Arthur B. Pardee, Department of Cell Growth, Dana-Farber Cancer Institute, D-810, 44 Binney Street, Boston, MA 02115. Phone: 617-632-3372; Fax: 617-632-4680; E-mail: arthur_pardee{at}dfci.harvard.edu.

We propose that the lethality of commonly used anticancer drugs, e.g., methotrexate and cis-platinum are due, at least in part, to an increase of the E2F-1–mediated apoptotic cascade. The drugs directly or indirectly decrease deoxynucleoside triphosphates. The E2F family acts to provide control of S phase by transcribing genes required for deoxynucleoside triphosphate and DNA synthesis. Thus, a mechanism for control of E2F-1 is essential, a signal safeguarding against aberrant or uncontrolled cell proliferation. We have proposed a feedback control by NTPs that down-regulates E2F-1. Here, we provide evidence in support of this hypothesis.

This article has been cited by other articles:

				X.-S. Miao, P. Song, R. E. Savage, C. Zhong, R.-Y. Yang, D. Kizer, H. Wu, E. Volckova, M. A. Ashwell, J. G. Supko, et al. Identification of the in Vitro Metabolites of 3,4-Dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione (ARQ 501; {beta}-Lapachone) in Whole Blood Drug Metab. Dispos., April 1, 2008; 36(4): 641 - 648. [Abstract] [Full Text] [PDF]

				A. O. Kaseb, K. Chinnakannu, D. Chen, A. Sivanandam, S. Tejwani, M. Menon, Q. P. Dou, and G. P.-V. Reddy Androgen Receptor and E2F-1 Targeted Thymoquinone Therapy for Hormone-Refractory Prostate Cancer Cancer Res., August 15, 2007; 67(16): 7782 - 7788. [Abstract] [Full Text] [PDF]

				M. S. Goligorsky How to keep kidneys safe while shrinking tumors: the conundrum of cisplatin action Am J Physiol Renal Physiol, July 1, 2007; 293(1): F50 - F51. [Full Text] [PDF]

				D. Reimer, S. Sadr, A. Wiedemair, S. Stadlmann, N. Concin, G. Hofstetter, E. Muller-Holzner, C. Marth, and A. G. Zeimet Clinical Relevance of E2F Family Members in Ovarian Cancer--An Evaluation in a Training Set of 77 Patients Clin. Cancer Res., January 1, 2007; 13(1): 144 - 151. [Abstract] [Full Text] [PDF]